Gary Horwith

2.3k total citations
17 papers, 1.5k citations indexed

About

Gary Horwith is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Gary Horwith has authored 17 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 7 papers in Molecular Biology and 7 papers in Epidemiology. Recurrent topics in Gary Horwith's work include Antimicrobial Resistance in Staphylococcus (4 papers), Antifungal resistance and susceptibility (3 papers) and Cancer therapeutics and mechanisms (3 papers). Gary Horwith is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (4 papers), Antifungal resistance and susceptibility (3 papers) and Cancer therapeutics and mechanisms (3 papers). Gary Horwith collaborates with scholars based in United States, Israel and Netherlands. Gary Horwith's co-authors include Ali Fattom, Robert Naso, Steve Fuller, Elias Anaissie, John R. Perfect, Nita L. Seibel, Mark J. DiNubile, Jeffrey L. Silber, Lily Lee and Eric J. Bow and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Gary Horwith

17 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Horwith United States 14 960 614 459 141 127 17 1.5k
Takayoshi Tashiro Japan 32 1.5k 1.6× 1.5k 2.5× 439 1.0× 126 0.9× 216 1.7× 141 2.7k
Yoshifumi Imamura Japan 26 1.1k 1.1× 1.2k 1.9× 530 1.2× 265 1.9× 149 1.2× 124 2.5k
Håkan Miörner Sweden 25 986 1.0× 926 1.5× 303 0.7× 147 1.0× 129 1.0× 49 1.7k
Louis de Repentigny Canada 28 1.7k 1.8× 1.3k 2.1× 311 0.7× 174 1.2× 164 1.3× 63 2.4k
Douglas S. Kernodle United States 26 1.2k 1.2× 494 0.8× 527 1.1× 222 1.6× 230 1.8× 50 2.0k
Ayşe Kalkancı Türkiye 22 741 0.8× 560 0.9× 255 0.6× 95 0.7× 66 0.5× 109 1.4k
Rodrigue Dessein France 18 390 0.4× 291 0.5× 421 0.9× 89 0.6× 157 1.2× 57 1.2k
Evangelos D. Anastassiou Greece 25 440 0.5× 394 0.6× 446 1.0× 122 0.9× 313 2.5× 81 1.7k
Hiroshi Watanabe Japan 23 475 0.5× 668 1.1× 417 0.9× 153 1.1× 297 2.3× 131 1.8k
S. G. Filler United States 16 1.4k 1.5× 1.1k 1.9× 159 0.3× 107 0.8× 105 0.8× 17 1.8k

Countries citing papers authored by Gary Horwith

Since Specialization
Citations

This map shows the geographic impact of Gary Horwith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Horwith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Horwith more than expected).

Fields of papers citing papers by Gary Horwith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Horwith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Horwith. The network helps show where Gary Horwith may publish in the future.

Co-authorship network of co-authors of Gary Horwith

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Horwith. A scholar is included among the top collaborators of Gary Horwith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Horwith. Gary Horwith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Schwartz, Michael D., Robert Raulli, WILLIAM B. COLEY, et al.. (2022). Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure. Journal of Medical Toxicology. 18(3). 187–197. 3 indexed citations
2.
Wolfe, Daniel, Eric M. Espeland, Yonghong Gao, et al.. (2020). Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older. Vaccine. 38(50). 7970–7976. 8 indexed citations
3.
Wathen, Lynne K., et al.. (2020). Using biodosimetry to enhance the public health response to a nuclear incident. International Journal of Radiation Biology. 97(sup1). S6–S9. 15 indexed citations
4.
Wagena, Edwin, et al.. (2008). The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: Results of a randomized, placebo-controlled phase 1/2 trial. Nicotine & Tobacco Research. 10(1). 213–218. 36 indexed citations
5.
Horwith, Gary. (2007). Phase 1 Safety and Pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug. 2 indexed citations
6.
Dickson, Rolland C., Norah A. Terrault, Michael B. Ishitani, et al.. (2005). Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transplantation. 12(1). 124–133. 33 indexed citations
7.
Rennard, Stephen I., Douglas E. Jorenby, Marco Fiore, et al.. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics. 78(5). 456–467. 142 indexed citations
8.
Fattom, Ali, Steve Fuller, Scott Winston, et al.. (2004). Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX®) in hemodialysis patients. Vaccine. 23(5). 656–663. 75 indexed citations
9.
Robbins, John B., Rachel Schneerson, Gary Horwith, Robert Naso, & Ali Fattom. (2004). Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. American Heart Journal. 147(4). 593–598. 30 indexed citations
10.
11.
Shinefield, Henry R., Steven Black, Ali Fattom, et al.. (2002). Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis. New England Journal of Medicine. 346(7). 491–496. 351 indexed citations
12.
Adedoyin, Adedayo, Christine E. Swenson, Lois E. Bolcsak, et al.. (2000). A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections. Antimicrobial Agents and Chemotherapy. 44(10). 2900–2902. 40 indexed citations
13.
Walsh, Thomas J., John W. Hiemenz, Nita L. Seibel, et al.. (1998). Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases. Clinical Infectious Diseases. 26(6). 1383–1396. 461 indexed citations
14.
Adedoyin, Adedayo, Christine E. Swenson, Gary Horwith, et al.. (1997). Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrobial Agents and Chemotherapy. 41(10). 2201–2208. 74 indexed citations
15.
Tacket, Carol O., Genevieve A. Losonsky, Michael D. Lubeck, et al.. (1992). Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine. 10(10). 673–676. 43 indexed citations
16.
Kalechman, Yona, Michael Albeck, Marc Gurwith, et al.. (1991). Protective and restorative role of AS101 in combination with chemotherapy.. PubMed. 51(5). 1499–503. 45 indexed citations
17.
Kalechman, Yona, et al.. (1991). Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.. PubMed. 51(20). 5614–20. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takayoshi Tashiro Breakdown of academic impact, for papers by Yoshifumi Imamura Breakdown of academic impact, for papers by Håkan Miörner Breakdown of academic impact, for papers by Louis de Repentigny Breakdown of academic impact, for papers by Douglas S. Kernodle Breakdown of academic impact, for papers by Ayşe Kalkancı Breakdown of academic impact, for papers by Rodrigue Dessein Breakdown of academic impact, for papers by Evangelos D. Anastassiou Breakdown of academic impact, for papers by Hiroshi Watanabe Breakdown of academic impact, for papers by S. G. Filler
Rankless by CCL
2026